Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension

Inclusion Criteria: * Essential hypertension not controlled at 5 mg bisoprolol or 5 mg amlodipine at least 4 weeks (definition of not controlled: SBP greater than or equal to (\>=) 140 millimeter of mercury (mmHg) with or without DBP \>= 90 mmHg) * Male or female subjects \>=18 years of age, without limitation on race * Medically accepted effective contraception if procreative potential exists (applicable for both male and female subjects until at least 90 days after the last dose of trial treatment) * Subjects who have signed the informed consent form before any trial related assessment Exclusion Criteria: * General contraindications of beta-blockers and/or calcium channel blockers * Previous and concurrent acute heart failure or during episodes of heart failure decompensation requiring intravenous inotropic therapy * Concurrent cardiogenic shock * Previous and concurrent second or third degree atrioventricular (AV) block (without a pacemaker) * Previous and concurrent sick sinus syndrome * Previous and concurrent sinoatrial block * Concurrent symptomatic bradycardia * Concurrent symptomatic hypotension * Previous and concurrent severe bronchial asthma or chronic obstructive pulmonary diseases * Previous and concurrent severe peripheral arterial occlusive diseases and Raynaud's syndrome * Untreated pheochromocytoma * Concurrent metabolic acidosis * Known hypersensitivity to bisoprolol, amlodipine, dihydropyridine derivates or to any of the excipients * Seated pulse rate less than 60 beats per minute (bpm) at screening * Any other anti-hypertensive drugs (other than bisoprolol and amlodipine) are used within 4 weeks prior to the screening visit * Use of any enzyme-modifying drugs acting on cytochrome P450 (CYP) 3A4 enzymes via inhibition (such as ketoconazole, itraconazole, ritonavir) or induction (such as rifampicin or hypericum perforatum) within 28 days before Day 1 of the trial * Other significant disease that in the Investigator's opinion that would exclude the subject from the trial, such as uncontrolled diabetes mellitus, severe liver and/or kidney dysfunction, decompensated cardiac failure * Any other condition or therapy which in the Investigator's opinion would pose a risk to the subject or interfere with the trial objectives * Concurrent alcohol and/or drug abuse * Known hypersensitivity to the trial treatments * Pregnancy and lactation period. All female subjects with reproductive potential must have a negative pregnancy serum test within the 7 days prior to enrollment * Known lack of subject compliance * Legal incapacity or limited legal capacity * Participation in another clinical trial within the previous 30 days * Persons directly involved in the execution of the protocol